---
schema_version: "secwatch.filing_event.v1"
accession: "0000010795-25-000019"
form_type: "8-K"
ticker: "BDX"
cik: "0000010795"
company_name: "BECTON DICKINSON & CO"
filed_at: "2025-02-05T23:59:59+00:00"
generated_at: "2026-05-27T02:20:25.139013+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# BD beats Q1 estimates, announces plan to separate Biosciences and Diagnostic Solutions

## Summary
- Q1 revenue $5.2B (+9.8% reported, +3.9% organic); adj. EPS $3.43 (+28.0% YoY); GAAP EPS $1.04.
- Company raised FY25 adjusted diluted EPS guidance at midpoint; completed $750M share repurchase.
- BD board authorized separation of Biosciences and Diagnostic Solutions; target completion in fiscal 2026.
- New BD (post-separation) expected FY24 revenue ~$17.8B; separated business ~$3.4B with ~30% adj. EBITDA margins.
- Investor Day (Feb 26, 2025) postponed; company to provide update closer to separation.

## SEC filing metadata
- accession: 0000010795-25-000019
- form_type: 8-K
- ticker: BDX
- cik: 0000010795
- company_name: BECTON DICKINSON & CO
- filed_at: 2025-02-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/10795/000001079525000019/0000010795-25-000019-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/10795/000001079525000019/bdx-20250205.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000010795-25-000019
- JSON: https://secwatch.observer/filing/0000010795-25-000019.json
- Plain text: https://secwatch.observer/filing/0000010795-25-000019.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.